Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1302 to 1351 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1302\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSLATION INITIATION FACTOR EIF-2B GAMMA SUBUNIT (EIF-2B GDP-GTP EXCHANGE FACTOR). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.473798\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
1.92792\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.245756048\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
EIF2B3\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1303\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSLATION INITIATION FACTOR EIF-2B EPSILON SUBUNIT (EIF-2B GDP-GTP EXCHANGE FACTOR). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
EIF2B5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1304\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAD9 HOMOLOG; CELL CYCLE CHECKPOINT CONTROL PROTEIN; RAD9 HOMOLOG (S. POMBE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0763771\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.310798\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245745146\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAD9A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1305\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PROLYL 4-HYDROXYLASE ALPHA-2 SUBUNIT PRECURSOR (EC 1.14.11.2) (4-PH ALPHA-2) (PROCOLLAGEN-PROLINE,2-OXOGLUTARATE-4-DIOXYGENASE ALPHA-2 SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0266534\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.108468\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725928\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
P4HA2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1306\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HYALURONAN BINDING PROTEIN 4; INTRACELLULAR ANTIGEN DETECTED BY MONOCLONAL ANTIBODY KI-1; INTRACELLULAR HYALURONAN-BINDING PROTEIN; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 3 INTERACTING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0335632\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.136588\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725832\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HABP4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1307\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN DISULFIDE ISOMERASE PRECURSOR (PDI) (EC 5.3.4.1) (PROLYL 4- HYDROXYLASE BETA SUBUNIT) (CELLULAR THYROID HORMONE BINDING PROTEIN) (P55). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.143784\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.58514\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725809\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
P4HB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1308\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAD1 HOMOLOG ISOFORM 1; EXONUCLEASE HOMOLOG RAD1; CELL CYCLE CHECKPOINT PROTEIN RAD1 A/B; RAD1-LIKE PROTEIN; CELL CYCLE CHECKPOINT PROTEIN HRAD1; DNA REPAIR EXONUCLEASE (REC1); DNA REPAIR PROTEIN RAD1; RAD1-LIKE DNA DAMAGE CHECKPOINT PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.874478\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.55876\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725477\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAD1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1309\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HOMEOBOX PROSPERO-LIKE PROTEIN PROX1 (PROX 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0419409\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.170682\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725384\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PROX1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1310\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HUS1 CHECKPOINT PROTEIN; HUS1 (S. POMBE) CHECKPOINT HOMOLOG; HUS1+-LIKE PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.201117\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.818463\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725219\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HUS1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1311\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0417836\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.170042\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245725174\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SERBP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1312\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"3-HYDROXYANTHRANILATE 3,4-DIOXYGENASE (EC 1.13.11.6) (3-HAO) (3-HYDROXYANTHRANILIC ACID DIOXYGENASE) (3-HYDROXYANTHRANILATE OXYGENASE). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0418885\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.170469\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.245725029\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
HAAO\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1313\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZINC FINGER PROTEIN-LIKE 1; ZINC-FINGER PROTEIN IN MEN1 REGION. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ZFPL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1314\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PROLYL 4-HYDROXYLASE ALPHA-1 SUBUNIT PRECURSOR (EC 1.14.11.2) (4-PH ALPHA-1) (PROCOLLAGEN-PROLINE,2-OXOGLUTARATE-4-DIOXYGENASE ALPHA-1 SUBUNIT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0333011\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.135522\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245724679\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
P4HA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1315\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HYDROXYACID OXIDASE 1 (EC 1.1.3.15) (HAOX1) (GLYCOLATE OXIDASE) (GOX). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.517862\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.1077\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245700052\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HAO1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1316\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TGF BETA-INDUCIBLE NUCLEAR PROTEIN 1; HAIRY CELL LEUKEMIA PROTEIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.448528\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.82552\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24569876\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1317\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ATP-DEPENDENT RNA HELICASE MGC2835; ATP-DEPENDENT RNA HELICASE; APOPTOSIS RELATED PROTEIN APR-5; DEAD BOX HELICASE 97 KDA. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.517911\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.10824\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245660361\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX54\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1318\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.479433\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.95163\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245657732\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDR74\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1319\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.269894\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.09872\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245644022\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARD1B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1320\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
THIOREDOXIN DOMAIN-CONTAINING 2; SPERM-SPECIFIC THIOREDOXIN; THIOREDOXIN DOMAIN-CONTAINING 2 (SPERMATOZOA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0247366\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.100732\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245568439\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TXNDC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1321\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
THIOREDOXIN (ATL-DERIVED FACTOR) (ADF) (SURFACE ASSOCIATED SULPHYDRYL PROTEIN) (SASP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0297584\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.121182\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245567824\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TXN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1322\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S ACIDIC RIBOSOMAL PROTEIN P1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.310893\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.26602\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245567211\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1323\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CENTROMERE PROTEIN J; CENTROSOMAL P4.1-ASSOCIATED PROTEIN; LYST-INTERACTING PROTEIN LIP1; LAG-3-ASSOCIATED PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.146257\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.595639\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24554638\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CENPJ\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1324\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"28S RIBOSOMAL PROTEIN S26, MITOCHONDRIAL PRECURSOR (MRP-S26) (MRP- S13). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0393961\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.160458\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.245522816\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
MRPS26\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1325\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
CHCHD4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1326\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ENHANCER OF RUDIMENTARY HOMOLOG. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.271803\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10704\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245522294\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ERH\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1327\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WD-REPEAT PROTEIN 12 (YTM1 HOMOLOG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.829705\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.37944\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245515529\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDR12\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1328\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NIF3-LIKE PROTEIN 1 (AMYOTROPHIC LATERAL SCLEROSIS 2 CHROMOSOMAL REGION CANDIDATE GENE PROTEIN 1) (MY018 PROTEIN) (MDS015). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.166892\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.679841\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245486812\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1329\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROBABLE ATP-DEPENDENT 61 KDA NUCLEOLAR RNA HELICASE (DEAD-BOX PROTEIN 21). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.280718\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.14368\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245451525\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDX56\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1330\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SACCHAROMYCES CEREVISIAE NIP7P HOMOLOG. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.455858\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.85732\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245438589\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NIP7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1331\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NNP-1 PROTEIN (NOVEL NUCLEAR PROTEIN 1) (NUCLEOLAR PROTEIN NOP52) (NOP52) (D21S2056E). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.213008\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.867932\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245420148\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RRP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1332\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NUCLEOLAR GTP-BINDING PROTEIN 1 (CHRONIC RENAL FAILURE GENE PROTEIN) (GTP-BINDING PROTEIN NGB). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.872438\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.55541\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245383233\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GTPBP4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1333\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYB-RELATED PROTEIN B (B-MYB). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.102811\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.419099\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245314353\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MYBL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1334\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AD24 PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.290237\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.18321\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24529627\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NOC3L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1335\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SUPPRESSOR OF SWI4 1 HOMOLOG (SSF-1) (PETER PAN HOMOLOG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0742746\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.302799\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245293412\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PPAN-P2RY11\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1336\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR ATF-6 BETA (ACTIVATING TRANSCRIPTION FACTOR 6 BETA) (ATF6-BETA) (CAMP RESPONSIVE ELEMENT BINDING PROTEIN-LIKE 1) (CAMP RESPONSE ELEMENT BINDING PROTEIN-RELATED PROTEIN) (CREB-RP) (G13 PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0331688\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.135226\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245284191\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CREBL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1337\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA SEGMENT ON CHROMOSOME 6(UNIQUE) 2654 EXPRESSED SEQUENCE; DNA SEGMENT ON CHROMOSOME X (UNIQUE) 2654 EXPRESSED SEQUENCE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0375954\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.153273\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245283905\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FAM50B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1338\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SFRS PROTEIN KINASE 2 ISOFORM B. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0349958\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.142675\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245283336\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SRPK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1339\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GTP BINDING PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.5466\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6.30537\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245282989\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GTPBP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1340\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SFRS PROTEIN KINASE 1; SR PROTEIN KINASE 1. \vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0417611\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.170257\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.24528272\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
SRPK1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1341\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
XAP-5 PROTEIN (HXC-26 PROTEIN). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
FAM50A\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1342\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERINE/THREONINE PROTEIN KINASE 23 (EC 2.7.1.37) (MUSCLE-SPECIFIC SERINE KINASE 1) (MSSK-1). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SRPK3\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1343\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIC-AMP-DEPENDENT TRANSCRIPTION FACTOR ATF-6 ALPHA (ACTIVATING TRANSCRIPTION FACTOR 6 ALPHA) (ATF6-ALPHA). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ATF6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1344\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAB3A INTERACTING PROTEIN ISOFORM ALPHA 1; RABIN3; SSX2 INTERACTING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.165502\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.674746\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245280446\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAB3IP\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1345\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROBABLE RRNA PROCESSING PROTEIN EBP2 (EBNA1 BINDING PROTEIN 2) (NUCLEOLAR PROTEIN P40). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.271421\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10693\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245201594\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EBNA1BP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1346\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAB3A INTERACTING PROTEIN (RABIN3)-LIKE 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.197255\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.804471\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245198397\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAB3IL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1347\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WD REPEAT DOMAIN 26. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.108431\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.442236\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.24518809\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
WDR26\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1348\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
J KAPPA-RECOMBINATION SIGNAL BINDING PROTEIN (RBP-J KAPPA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.517438\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.11039\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245185961\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RBPJ\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1349\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHANCER-BINDING PROTEIN 2 (HIV-EP2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0401322\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.163681\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245185452\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIVEP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1350\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZINC FINGER PROTEIN 40 (HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHANCER- BINDING PROTEIN 1) (HIV-EP1) (MAJOR HISTOCOMPATIBILITY COMPLEX BINDING PROTEIN 1) (MBP-1) (POSITIVE REGULATORY DOMAIN II BINDING FACTOR 1) (PRDII-BF1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0471496\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.192302\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245185177\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIVEP1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1351\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HUMAN IMMUNODEFICIENCY VIRUS TYPE I ENHANCER BINDING PROTEIN 3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0391877\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.159829\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.245185167\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HIVEP3\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/